Idera Pharmaceuticals Inc (IDRA) Rises A lot Today, Is Now One of The Best Performer

September 17, 2017 - By Linda Rogers

Investors sentiment increased to 3.31 in Q4 2016. Its up 1.26, from 2.05 in 2016Q3. It increased, as 9 investors sold Idera Pharmaceuticals Inc shares while 7 reduced holdings. 14 funds opened positions while 39 raised stakes. 96.26 million shares or 180.02% more from 34.38 million shares in 2016Q3 were reported.
Leavell Investment Mgmt reported 81,271 shares. Northern Trust Corporation has 0% invested in Idera Pharmaceuticals Inc (NASDAQ:IDRA). State Board Of Administration Of Florida Retirement Sys reported 19,240 shares. Alliancebernstein L P accumulated 77,300 shares. Alyeska Limited Partnership has invested 0.01% in Idera Pharmaceuticals Inc (NASDAQ:IDRA). State Street has invested 0% of its portfolio in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Proshare Advsrs Ltd Liability owns 16,652 shares or 0% of their US portfolio. Rhumbline Advisers accumulated 0% or 101,752 shares. Morgan Stanley holds 316,278 shares or 0% of its portfolio. Citigroup Incorporated reported 117,481 shares stake. Natixis reported 0.05% in Idera Pharmaceuticals Inc (NASDAQ:IDRA). 10.27 million were accumulated by Baker Bros Advsrs Ltd Partnership. Ra Management Ltd Liability Co reported 2.25M shares. D E Shaw And has invested 0% of its portfolio in Idera Pharmaceuticals Inc (NASDAQ:IDRA). Amer Gru Incorporated Inc reported 51,198 shares.

Since May 1, 2017, it had 0 buys, and 1 insider sale for $1.02 million activity. $1.02M worth of Idera Pharmaceuticals Inc (NASDAQ:IDRA) was sold by Pillar Invest Corp on Monday, May 1.

The stock of Idera Pharmaceuticals Inc (NASDAQ:IDRA) is a huge mover today! The stock increased 5.50% or $0.11 on September 15, reaching $2.11. About 1.77 million shares traded or 77.17% up from the average. Idera Pharmaceuticals Inc (NASDAQ:IDRA) has risen 21.13% since September 17, 2016 and is uptrending. It has outperformed by 4.43% the S&P500.
The move comes after 5 months positive chart setup for the $315.72M company. It was reported on Sep, 17 by Barchart.com. We have $2.28 PT which if reached, will make NASDAQ:IDRA worth $25.26 million more.

Investors wait Idera Pharmaceuticals Inc (NASDAQ:IDRA) to report on October, 27. its quarterly earnings Wall Street analysts expect $-0.12 EPS, down $0.02 or 20.00 % from last year’s $-0.1 same quarter earnings. Idera Pharmaceuticals Inc’s Wall Street analysts see -14.29 % EPS growth, taking into account the $-0.14 EPS reproted in the previous quarter,

Idera Pharmaceuticals Inc (NASDAQ:IDRA) Ratings Coverage

Among 3 analysts covering Idera Pharma (NASDAQ:IDRA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Idera Pharma had 4 analyst reports since January 6, 2016 according to SRatingsIntel. The firm earned “Outperform” rating on Wednesday, February 1 by Wedbush. The rating was maintained by Piper Jaffray with “Buy” on Monday, September 11. Wedbush initiated Idera Pharmaceuticals Inc (NASDAQ:IDRA) on Wednesday, January 6 with “Outperform” rating.

More important recent Idera Pharmaceuticals Inc (NASDAQ:IDRA) news were published by: Seekingalpha.com which released: “Idera Pharmaceuticals: This ESMO Winner Is A Buy” on September 15, 2017, also Globenewswire.com published article titled: “Idera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment in …”, Nasdaq.com published: “Idera Pharmaceuticals (IDRA) Jumps: Stock Rises 14.4%” on September 12, 2017. More interesting news about Idera Pharmaceuticals Inc (NASDAQ:IDRA) was released by: Fool.com and their article: “Here’s Why Idera Pharmaceuticals, Inc. Is Surging Today” with publication date: September 11, 2017.

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The company has market cap of $315.72 million. The Firm utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor targeting technology and third-generation antisense (3GA) technology. It currently has negative earnings. Using TLR technology, the Company creates synthetic oligonucleotide drug candidates to act by modulating the activity of specific TLRs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.